I’m a reproductive psychiatrist. The Lindsay Clancy trial will cause terrible damage to my field Rather than prompting a renaissance in treating postpartum mental illness, the trial will make things worse

https://www.statnews.com/2026/09/01/lindsay-clancy-trial-verdict-postpartum-psychosis-psychiatry/ By Jennifer Adaeze OkwerekwuSept. 1, 2026 Okwerekwu is a reproductive psychiatrist in private practice.

How Trump’s latest pharma deals may undermine efforts to rein in drug costs In agreeing to lower prices in Medicaid, drugmakers are exempt from lowering prices in Medicare

https://www.statnews.com/2026/09/02/trump-most-favored-nation-drug-pricing-industry-analysts-skeptical/ By John WilkersonSept. 2, 2026 Washington Correspondent

Diabetes association CEO: What an independent review says happened at the ADA’s controversial June conference And how we can move forward

https://www.statnews.com/2026/09/01/american-diabetes-association-june-conference-independent-review/ By Charles "Chuck" HendersonSept. 1, 2026 Henderson is the CEO of the American Diabetes Association.

ADA review of members’ expulsion denies group censored opinions, called in police Five attendees were removed from conference because of conduct, according to findings

https://www.statnews.com/2026/09/01/ada-members-review-june-expulsion-denies-censoring-opinions-calling-new-orleans-police/ By Elizabeth CooneySept. 1, 2026 Cardiovascular Disease Reporter

Pharmacogenomics Education Series: How to Implement Pharmacogenomics into Medication Management (Module 3) September 16, 2026

https://www.dhaj7-cepo.com/content/pharmacogenomics-education-series-module-3?utm_source=newsletter&utm_medium=email&utm_campaign=september2026 How to Implement Pharmacogenomics into Medication Management Wednesday, September 16, 2026, at 12:00 p.m. ET Learn how to incorporate pharmacogenomic data into clinical decision-making and apply pharmacogenomic principles in real-world clinical settings.

OPDP’s Latest Reminder on Preapproval Promotion September 2, 2026 By Sarah Wicks & Dara Katcher Levy & Jeffrey N. Wasserstein —

https://www.thefdalawblog.com/2026/09/opdps-latest-reminder-on-preapproval-promotion/?utm_source=rss&utm_medium=rss&utm_campaign=opdps-latest-reminder-on-preapproval-promotion For anyone who thought FDA’s Office of Prescription Drug Promotion (OPDP) had lost interest in pre-approval promotion, think again. On August 21, 2026, OPDP issued an Untitled Letter to Alar Pharmaceuticals concerning promotional claims for ALA-3000 injection, an investigational extended-release ketamine product being developed for treatment-resistant depression (TRD) displayed at an exhibit booth at the American Psychiatric Association’s 2026 Annual Meeting earlier this year.

Health Ministry investigating another suspected Ebola case after traveler returns from DR Congo ByJERUSALEM POST STAFF AUGUST 31, 2026 22:26 +...

Health Ministry investigating another suspected Ebola case after traveler returns from DR Congo The person will be treated in isolation under procedures for handling high-risk infectious diseases and will be transferred to Ichilov Hospital. https://www.jpost.com/health-and-wellness/article-907180 ByJERUSALEM POST STAFF AUGUST 31, 2026 22:26 https://www.jpost.com/health-and-wellness